Adenoviral Astrocyte-Specific Expression of BDNF in the Striata of Mice Transgenic for Huntington’s Disease Delays the Onset of the Motor Phenotype

被引:0
作者
Leticia Arregui
Jorge A. Benítez
Luis F. Razgado
Paula Vergara
Jose Segovia
机构
[1] Centro de Investigación y de Estudios Avanzados del IPN,Departamento de Fisiología, Biofísica y Neurociencias
[2] Universidad Autónoma Metropolitana Cuajimalpa,Departamento de Ciencias Naturales, DCNI
[3] University of California,Ludwig Institute for Cancer Research
来源
Cellular and Molecular Neurobiology | 2011年 / 31卷
关键词
Brain-derived neurotrophic factor; Huntington’s disease; Glial fibrillary acidic protein promoter; Adenovirus; Gene therapy;
D O I
暂无
中图分类号
学科分类号
摘要
Huntington’s disease (HD) is a neurodegenerative disorder characterized by motor, cognitive, and psychiatric symptoms. The most characteristic structural feature of this disease is neurodegeneration accompanied by gliosis in the striatum. BDNF has been proposed to protect striatal neurons from degeneration, because it is an important survival factor for these neurons from development to adulthood. Considering the extensive gliosis and the survival effects of BDNF, we constructed an adenovirus to express a BDNF cDNA in astrocyte cells using a promoter of the glial fibrillary acidic protein gene. Cells stably transfected in vitro with a BDNF cDNA driven by this promoter expressed BDNF and responded to external stimuli increasing BDNF production. When the vector was applied into the striata of mice transgenic for HD, long-term expression of the transgene was observed, associated with a delay of onset of the motor phenotype of the R6/2 HD transgenic mice. The present data indicate that the striatal expression of BDNF is a potential adjuvant for the treatment of HD.
引用
收藏
页码:1229 / 1243
页数:14
相关论文
共 24 条
  • [1] Adenoviral Astrocyte-Specific Expression of BDNF in the Striata of Mice Transgenic for Huntington's Disease Delays the Onset of the Motor Phenotype
    Arregui, Leticia
    Benitez, Jorge A.
    Razgado, Luis F.
    Vergara, Paula
    Segovia, Jose
    CELLULAR AND MOLECULAR NEUROBIOLOGY, 2011, 31 (08) : 1229 - 1243
  • [2] Striatal oxidative damage parallels the expression of a neurological phenotype in mice transgenic for the mutation of Huntington's disease
    Pérez-Severiano, F
    Ríos, C
    Segovia, J
    BRAIN RESEARCH, 2000, 862 (1-2) : 234 - 237
  • [3] Effects of chronic stress on the onset and progression of Huntington's disease in transgenic mice
    Mo, Christina
    Renoir, Thibault
    Hannan, Anthony J.
    NEUROBIOLOGY OF DISEASE, 2014, 71 : 81 - 94
  • [4] Age-dependent changes in nitric oxide synthase activity and protein expression in striata of mice transgenic for the Huntington's disease mutation
    Pérez-Severiano, F
    Escalante, B
    Vergara, P
    Ríos, C
    Segovia, J
    BRAIN RESEARCH, 2002, 951 (01) : 36 - 42
  • [5] Dietary arginine alters time of symptom onset in Huntington's disease transgenic mice
    Deckel, AW
    Volmer, P
    Weiner, R
    Gary, KA
    Covault, J
    Sasso, D
    Schmerler, N
    Watts, D
    Yan, Z
    Abeles, I
    BRAIN RESEARCH, 2000, 875 (1-2) : 187 - 195
  • [6] Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation
    Carter, RJ
    Lione, LA
    Humby, T
    Mangiarini, L
    Mahal, A
    Bates, GP
    Dunnett, SB
    Morton, AJ
    JOURNAL OF NEUROSCIENCE, 1999, 19 (08) : 3248 - 3257
  • [7] Increased Formation of Reactive Oxygen Species, but No Changes in Glutathione Peroxidase Activity, in Striata of Mice Transgenic for the Huntington's Disease Mutation
    Francisca Pérez-Severiano
    Abel Santamaría
    José Pedraza-Chaverri
    Omar N. Medina-Campos
    Camilo Ríos
    José Segovia
    Neurochemical Research, 2004, 29 : 729 - 733
  • [8] Nicotinamide improves motor deficits and upregulates PGC-1α and BDNF gene expression in a mouse model of Huntington's disease
    Hathorn, Tyisha
    Snyder-Keller, Abigail
    Messer, Anne
    NEUROBIOLOGY OF DISEASE, 2011, 41 (01) : 43 - 50
  • [9] Increased formation of reactive oxygen species, but no changes in glutathione peroxidase activity, in striata of mice transgenic for the Huntington's disease mutation
    Pérez-Severiano, F
    Santamariá, A
    Pedraza-Chaverri, J
    Medina-Campos, ON
    Ríos, C
    Segovia, J
    NEUROCHEMICAL RESEARCH, 2004, 29 (04) : 729 - 733
  • [10] Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice
    Dedeoglu, A
    Kubilus, JK
    Yang, LC
    Ferrante, KL
    Hersch, SM
    Beal, MF
    Ferrante, RJ
    JOURNAL OF NEUROCHEMISTRY, 2003, 85 (06) : 1359 - 1367